| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT07164443 A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant… |
date change Primary completion moved earlier: 2028-05-30 -> 2027-12-29 |
| 2026-06-06 | NCT07164443 A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant… |
date change Completion moved earlier: 2028-05-30 -> 2027-12-29 |
| 2026-06-06 | NCT07225946 A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic… |
Trial sites expanded: 117 -> 136 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07164443 | A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant… | Metastatic Castration-resistant Prostate Neoplasms | Recruiting |
| NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic… | Prostatic Neoplasms, Castration-Resistant | Recruiting |
| Phase 1 | |||
| NCT05818683 | A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic… | Metastatic Castration-resistant Prostate Neoplasms | Recruiting |
| NCT06095089 | A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | Prostatic Neoplasms | Recruiting |
| NCT07082920 | A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | Prostatic Neoplasms | Recruiting |
| NCT07319871 | A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of… | Prostatic Neoplasms | Recruiting |
| NCT04644770 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2… | Prostatic Neoplasms | Active, Not Recruiting |
| NCT04898634 | A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2)… | Prostatic Neoplasms | Active, Not Recruiting |